Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023. 

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.

---

Naloxone - Patient Safety Alert

27th October 2015

NHS England has produced a second Patient Safety Alert (NHS/PSA/Re/2015/009) in relation to inappropriate doses of naloxone in patients on long-term opioid treatment. The Stage Two Resource Alert points to the resources that have been developed in response to the Stage One Alert issued in November 2014 (NHS/PSA/W/2014/016R; see our news item 27 November 2014). The new alert is intended to support all providers of NHS funded care to ensure local protocols and training related to use of naloxone reflect best practice, and can be downloaded from the link below.

Editor’s note: The information from the original stage one alert is reflected in the PCF Opioid antagonist monograph. In addition there is information on even lower initial doses (20microgram IV) being used for the reversal of respiratory depression caused by the medicinal use of opioids (naloxone) as recommended by the American Pain Society

click here to view